208 related articles for article (PubMed ID: 24275323)
1. The cardioprotective effects of mineralocorticoid receptor antagonists.
van den Berg TN; Rongen GA; Fröhlich GM; Deinum J; Hausenloy DJ; Riksen NP
Pharmacol Ther; 2014 Apr; 142(1):72-87. PubMed ID: 24275323
[TBL] [Abstract][Full Text] [Related]
2. The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury.
Dragasevic N; Jakovljevic V; Zivkovic V; Draginic N; Andjic M; Bolevich S; Jovic S
Can J Physiol Pharmacol; 2021 Jan; 99(1):18-29. PubMed ID: 32799671
[TBL] [Abstract][Full Text] [Related]
3. Why are mineralocorticoid receptor antagonists cardioprotective?
Chai W; Danser AH
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Mihailidou AS; Loan Le TY; Mardini M; Funder JW
Hypertension; 2009 Dec; 54(6):1306-12. PubMed ID: 19841288
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor and cardiac arrhythmia.
Gravez B; Tarjus A; Jaisser F
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
Galuppo P; Bauersachs J
Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
Funder JW
Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
[TBL] [Abstract][Full Text] [Related]
8. The cardioprotective effects of metformin.
El Messaoudi S; Rongen GA; de Boer RA; Riksen NP
Curr Opin Lipidol; 2011 Dec; 22(6):445-53. PubMed ID: 21897229
[TBL] [Abstract][Full Text] [Related]
9. Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury.
Ashton AW; Le TY; Gomez-Sanchez CE; Morel-Kopp MC; McWhinney B; Hudson A; Mihailidou AS
Mol Endocrinol; 2015 Aug; 29(8):1144-55. PubMed ID: 26121234
[TBL] [Abstract][Full Text] [Related]
10. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases.
Barrera-Chimal J; Bonnard B; Jaisser F
Annu Rev Physiol; 2022 Feb; 84():585-610. PubMed ID: 35143332
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Lother A; Moser M; Bode C; Feldman RD; Hein L
Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction.
Smits GJ; McVey M; Cox BF; Perrone MH; Clark KL
J Pharmacol Exp Ther; 1998 Aug; 286(2):611-8. PubMed ID: 9694911
[TBL] [Abstract][Full Text] [Related]
13. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term effects of melatonin on myocardial post-ischemic recovery.
Lochner A; Genade S; Davids A; Ytrehus K; Moolman JA
J Pineal Res; 2006 Jan; 40(1):56-63. PubMed ID: 16313499
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease.
Parker BM; Wertz SL; Pollard CM; Desimine VL; Maning J; McCrink KA; Lymperopoulos A
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486399
[TBL] [Abstract][Full Text] [Related]
16. Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts.
Balakumar P; Singh H; Reddy K; Anand-Srivastava MB
J Cardiovasc Pharmacol; 2009 Sep; 54(3):204-12. PubMed ID: 19568176
[TBL] [Abstract][Full Text] [Related]
17. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
[TBL] [Abstract][Full Text] [Related]
18. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system.
Mihailidou AS; Funder JW
Steroids; 2005; 70(5-7):347-51. PubMed ID: 15862816
[TBL] [Abstract][Full Text] [Related]
19. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
[TBL] [Abstract][Full Text] [Related]
20. [Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction].
Hayashi M
J Cardiol; 2004 Feb; 43(2):88-91. PubMed ID: 15046031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
